×

5-substituted pyrazolo[4,3-D]pyrimidin-7-ones

  • US 6,235,742 B1
  • Filed: 10/21/1998
  • Issued: 05/22/2001
  • Est. Priority Date: 10/24/1997
  • Status: Expired due to Fees
0
Associated Cases
0
Associated Defendants
0
Product Citations
0
Petitions
63
Forward Citations
2
Assignments
First Claim
Patent Images

1. A compound of the formula (I) whereinRa is C3-C6 alkyl;

  • R1 is H or C1-C4 alkyl;

    each of R2 and R3 is independently selected from H and C1-C4 alkyl, or R2 is H or C1-C4 alkyl and R3 is OH, C2-C4 alkanoyloxy or fluoro, or R2 and R3 when taken together represent C2-C6 alkylene, or R2 and R3 when taken together with the carbon atom to which they are attached represent a carbonyl group;

    Ar is either (a)  

    wherein each of R4, R5 and R6 is independently selected from H, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkoxy-Z—

    , halo, halo(C1-C4)alkyl, phenoxy, optionally substituted by up to three substitutents each of which substituent is independently selected from halo, C1-4 alkyl, and C1-C4 alkoxy, nitro, hydroxy, hydroxy-Z—

    , C2-C4 alkanoyl, amino, amino-Z—

    , (C1-C4 alkyl)NH, (C1-C4 alkyl)2N—

    , (C1-C4 alkyl)NH—

    Z—

    , (C1-C4 alkyl)2N—

    Z—

    , —

    COOH, —

    Z—

    COOH, —

    COO(C1-C4 alkyl), —

    Z—

    COO(C1-C4 alkyl) C1-C4 alkanesulphonamido, C1-C4 alkanesulphonamido-Z—

    , halo(C1-C4)alkanesulphonamido, halo(C1-C4)alkanesulphonamido-Z—

    , C1-C4 alkanamido, C1-C4 alkanamido-Z—

    , HOOC—

    Z—

    NH—

    , HOOC—

    Z—

    NH—

    Z—

    , (C1-C4 alkyl)OOC—

    Z—

    NH—

    , (C1-C4 alkyl)OOC—

    Z—

    NH—

    Z—

    , C1-C4 alkyl-NH—

    SO2—

    NH—

    , C1-C4 alkyl-NH—

    SO2—

    NH—

    Z—

    , (C1-C4 alkyl)2—

    N—

    SO2—

    NH—

    , (C1-C4 alkyl)2—

    N—

    SO2—

    NH—

    Z—

    , C1-C4 alkoxy CH═

    CH—

    Z—

    CONH—

    , C1-C4 alkoxy CH═

    CHCONH C1-C4 alkyl-SO2—

    N(C1-C4 alkyl)-, C1-C4 alkyl-SO2—

    N(C1-C4 alkyl)—

    Z—

    , (C1-C4 alkyl)NH—

    Z—

    SO2—

    NH—

    , (C1-C4 alkyl)2N—

    Z—

    SO2—

    NH—

    , (C1-C4 alkyl)NH—

    Z—

    SO2—

    NH—

    Z—

    , (C1-C4 alkyl)2N—

    Z—

    SO2—

    NH—

    Z—

    , benzenesulphonamido, optionally ring substituted by up to three substitutents each of which is independently selected from halo, C1-4 alkyl, and C1-C4 alkoxy, C1-C4 alkanoyl-N(C1-C4 alkyl)-, C1-C4 alkanoyl-N(C1-C4 alkyl)-Z—

    , C1-C4 alkoxycarbonyl-CH(CH2OH)NHSO2—

    , —

    SO3H, —

    SO2NH2, H2NOC—

    CH(CH2OH)—

    NHSO2—

    , HOOC—

    Z—

    O—

    , and (C1-C4 alkyl)OOC—

    Z—

    O—

    , or optionally one of R4, R5 and R6 is a G-Het group and wherein the others of R4, R5 and R6 are independently selected from the R4, R5 and R6 subsituents listed above;

    Z is C1-C4 alkylene, G is a direct link, Z, O, —

    SO2NH—

    , SO2, or —

    Z—

    N(C1-C4 alkyl)SO2—

    , Het is a 5- or 6-membered heterocyclic group containing heteroatoms selected from the groups consisting of 1, 2, 3 or 4 nitrogen heteroatoms; and

    1 or 2 nitrogen heteroatoms and 1 sulphur heteroatom or 1 oxygen heteroatom;

    or the heterocyclic group is furanyl or thiophenyl;

    wherein the Het group is saturated or partially or fully unsaturated and optionally substituted by up to 3 substituents, wherein each substituent is independently selected from C1-C4 alkyl, oxo, hydroxy, halo, and halo(C1-C4) alkyl;

    or (b) any one of the following bicyclic groups;

    benzodioxolanyl, benzodioxanyl, benzimidazolyl, quinolinyl, indolyl, quinazolinyl, isoquinolinyl, benzotriazolyl, benzofuranyl, benzothiophenyl, quinoxalinyl, or phthalizinyl, wherein said bicyclic Ar groups are linked to the neighbouring —

    C(R2R3)—

    group via the benzo ring portion, and wherein the heterocyclic portion of said bicyclic Ar group is optionally partially or fully saturated, said group being optionally substituted by one or more of C1-C4 alkyl, halo, hydroxy, oxo, amino, and C1-C4 alkoxy;

    or a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable solvate of the compound or the salt.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×